Medical treatment of patients with benign prostatic hyperplasia with 5α-reductase inhibitors


DOI: https://dx.doi.org/10.18565/urology.2019.4.175-179

L.G. Spivak, D.V. Platonova, D.D. Yagudaev

1) FGAOU VO I.M. Sechenov First Moscow State Medical University of Minzdrav of Russia, Moscow, Russia; 2) FGBUZ CH №85 FMBA of Russia, Moscow, Russia
The results of studies comparing the therapy of benign prostatic hyperplasia with 5α-reductase inhibitors and α1-blockers are presented in the article. Benign prostatic hyperplasia is a common disease in older men. Pathogenetic treatment allows to block a progression of prostatic hyperplasia and is of greatest interest in the treatment of this disease. The obtained data reliably demonstrate the advantage and safety of long-term pathogenetic therapy with dutasteride compared with symptomatic tamsulosin monotherapy with regard to quality of life and subjective symptoms. In addition, pathogenetic therapy provides better results in preventing the progression of benign prostatic hyperplasia.

About the Autors


Corresponding author: Platonova Darina Vladimirovna– researcher, urologist at the policlinic №1, FGBUZ CH №85 FMBA of Russia, Moscow, Russia; e-mail: darina_mma@mail.ru


Similar Articles


Бионика Медиа